ライフサイエンスコーパス: Pneumocystis carinii pneumonia

1 laria, toxoplasmosis, cryptosporidiosis, and Pneumocystis carinii pneumonia).

2 tible to opportunistic infections, including Pneumocystis carinii pneumonia.

3 seful in predicting outcome in patients with Pneumocystis carinii pneumonia.

4 ycardia and right heart strain are common in Pneumocystis carinii pneumonia.

5 n = 6), including 2 patients who died of non-Pneumocystis carinii pneumonia.

6 now a more frequent cause of admission than Pneumocystis carinii pneumonia.

7 substantially to respiratory failure during Pneumocystis carinii pneumonia.

8 functional lymphocytes and therefore develop Pneumocystis carinii pneumonia.

9 ely used in the treatment and prophylaxis of Pneumocystis carinii pneumonia.

10 corticosteroid-immunosuppressed rat model of Pneumocystis carinii pneumonia.

11 %; OR, 4.9; 95% CI, 1.0-24), and to have had Pneumocystis carinii pneumonia (52.9% vs. 11.8%; OR, 7.6

12 84%), Mycobacterium avium complex (73%), and Pneumocystis carinii pneumonia (69%), and the positive p

13 how significant activity in the treatment of Pneumocystis carinii pneumonia, an opportunistic infecti

14 unistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus ret

15 variables have been studied in patients with Pneumocystis carinii pneumonia and acquired immunodefici

16 admission electrocardiogram in patients with Pneumocystis carinii pneumonia and AIDS in an attempt to

17 tive care should include prophylaxis against Pneumocystis carinii pneumonia and esophageal candidiasi

18 aking corticosteroids are at greater risk of Pneumocystis carinii pneumonia and may benefit from prop

19 tiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis).

20 cy causes recurrent sinopulmonary infection, Pneumocystis carinii pneumonia, and Cryptosporidium parv

21 secondary transplanted mice, attenuation of Pneumocystis carinii pneumonia, and no evidence of lymph

22 ally to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii to

23 d Enterobacter cloacae, Serratia marcescens, Pneumocystis carinii pneumonia, and unknown (7%, 1 of 15

24 Although the clinical aspects of Pneumocystis carinii pneumonia are well characterized, t

25 t whether there was geographic clustering of Pneumocystis carinii pneumonia cases among patients with

26 of < 50 cells/microL and was associated with Pneumocystis carinii pneumonia, cytomegalovirus meningoe

27 Pneumocystis carinii pneumonia did not develop in either

28 of lymphopenia, and included single cases of Pneumocystis carinii pneumonia, disseminated varicella z

29 99 cells/mm3, the incidence of bacterial and Pneumocystis carinii pneumonia each increased an average

30 ly trends in survival after the diagnosis of Pneumocystis carinii pneumonia for 19,607 patients in Ca

31 Pneumocystis carinii pneumonia has decreased substantial

32 of the new compounds were effective against Pneumocystis carinii pneumonia in the immunosuppressed r

33 was not helpful in other diseases including Pneumocystis carinii pneumonia, infection with Cryptococ

34 Pneumocystis carinii pneumonia is a hallmark disease ass

35 Pneumocystis carinii pneumonia is also common in this se

36 Pneumocystis carinii pneumonia is an important cause of

37 Pneumocystis carinii pneumonia is associated with a high

38 is the drug of choice for the prevention of Pneumocystis carinii pneumonia, many patients cannot tol

39 any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium comp

40 Pneumocystis carinii pneumonia, Mycobacterium avium comp

41 Pneumocystis carinii pneumonia (OR = 0.24, p = 0.001), m

42 To examine survival after diagnosis of Pneumocystis carinii pneumonia (PCP) and factors associa

43 The epidemiology of Pneumocystis carinii pneumonia (PCP) and its geographic

44 h human immunodeficiency virus (HIV)-related Pneumocystis carinii pneumonia (PCP) and respiratory fai

45 Pneumocystis carinii pneumonia (PCP) can be diagnosed by

46 The clinical severity of Pneumocystis carinii pneumonia (PCP) correlates closely

47 With decreasing incidence of pneumocystis carinii pneumonia (PCP) in AIDS as a result

48 ons and their evaluation as prodrugs against Pneumocystis carinii pneumonia (PCP) in an immunosuppres

49 ination with sulphonamides is active against Pneumocystis carinii pneumonia (PCP) in animals.

50 The prevalence of Pneumocystis carinii pneumonia (PCP) in humans caused by

51 During Pneumocystis carinii pneumonia (PCP) in mice, the degree

52 Pneumocystis carinii pneumonia (PcP) is a clinically imp

53 Necropsy studies from Africa have shown that Pneumocystis carinii pneumonia (PCP) is common in infant

54 amethoxazole (TMP-SMZ) is the most effective Pneumocystis carinii pneumonia (PCP) prophylactic agent,

55 Pneumocystis carinii pneumonia (PCP) remains a major cau

56 Pneumocystis carinii pneumonia (PcP) remains among the m

57 Pneumocystis carinii pneumonia (PCP) remains the most co

58 Despite recent declines in incidence, Pneumocystis carinii pneumonia (PCP) remains the most co

59 rs for the development of a first episode of Pneumocystis carinii pneumonia (PCP) were investigated i

60 e Mycobacterium avium complex (MAC) disease, Pneumocystis carinii pneumonia (PCP), and cytomegaloviru

61 ociated respiratory infections, most notably Pneumocystis carinii pneumonia (PCP), but also bacterial

62 principal diagnosis of lung disease; 11 had Pneumocystis carinii pneumonia (PCP), one of whom was co

63 en shown to contribute to lung injury during Pneumocystis carinii pneumonia (PCP), there are conflict

64 e in pulmonary damage and dysfunction during Pneumocystis carinii pneumonia (PcP).

65 able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP).

66 unodeficiency virus (HIV) infection has been Pneumocystis carinii pneumonia (PCP).

67 tovaquone in the prevention and treatment of Pneumocystis carinii pneumonia (PCP).

68 There were 145 episodes of Pneumocystis carinii pneumonia (PCP).

69 provide a new method for rapid diagnosis of Pneumocystis carinii pneumonia (PCP).

70 for community-acquired pneumonia, including Pneumocystis carinii pneumonia (PCP; patients), and 192

71 sk for preventable opportunistic infections (Pneumocystis carinii pneumonia [PCP] and disseminated My

72 ulfamethoxazole (TMP-SMX) is widely used for Pneumocystis carinii pneumonia prophylaxis in human immu

73 Pneumocystis carinii pneumonia remains a major cause of

74 Pneumocystis carinii pneumonia remains a serious complic

75 gory (RR2.0, 95% CI 1.43 to 2.76), and prior Pneumocystis carinii pneumonia (RR 3.88, 95% CI 1.65 to

76 lnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome).

77 concentrations to treat severe cases of the Pneumocystis carinii pneumonia typical of HIV infection.

78 The role of SP-D in host defense against Pneumocystis carinii pneumonia was assessed using SP-D k

79 Pneumocystis carinii pneumonia was diagnosed in one and

80 Pneumocystis carinii pneumonia was reported in two patie

81 A 49-year-old male with Pneumocystis carinii pneumonia was seen at Bellevue Hosp

82 Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstr